Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma

Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma

Background Tumor-targeted therapy causes impressive tumor regression, but the emergence of resistance limits long-term survival benefits in patients. Little information is available on the role of the myeloid cell network, especially dendritic cells (DC) during tumor-targeted therapy.Methods Here, w...

Full description

Bibliographic Details
Main Authors: Ian F Hermans, Christoph H Tripp, Florian Hornsteiner, Zlatko Trajanoski, Patrizia Stoitzner, Marc Schmitz, Natascha Hermann-Kleiter, Francesca Finotello, Janine Vierthaler, Helen Strandt, Antonia Resag, Zhe Fu, Markus Ausserhofer, Sophie Dieckmann, Markus Kanduth, Kathryn Farrand, Sarah Bregar, Niloofar Nemati, Athanasios Seretis, Sudhir Morla, David Mullins, Guido Wollmann, Franca Ronchese
Format: Article
Language:English
Published: BMJ Publishing Group 2024-04-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/4/e008606.full

Similar Items

Similar Items